Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Colorectal Cancer Reports
Erschienen in: Current Colorectal Cancer Reports 2/2013

01.06.2013 | Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer

verfasst von: Anya Litvak, Leonard Saltz

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

R0 resection has proved curative in a subset of patients with colorectal liver metastases. Unfortunately, the incidence of recurrence is high. For this reason, chemotherapy has been used at the preoperative and/or postoperative settings in clearly resectable disease in an attempt to eradicate micrometastasis and, hopefully, increase the oncological benefit of resection. For patients whose disease is not resectable but would become resectable as a result of a substantial response to treatment, chemotherapy is used to “convert” unresectable to resectable disease. This paper will review the use of perioperative chemotherapy, discuss issues regarding administration of chemotherapy before or after surgery, and review evidence regarding the use of specific cytotoxic and targeted agents.
Literatur
1.
2.
3.
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomized controlled trial. Lancet. 2008;371:1007–16. This is the first trial to demonstrate the oncological benefit of perioperative chemotherapy in liver resection.PubMedCrossRef
4.
Mitry E, Fields A, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. JCO. 2008;26:4906–11.CrossRef
5.
Nordlinger B, Sorbye H, Glimelius B, et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. JCO. 2012 (suppl; abstr 3508).
6.
Saltz, Leonard. Curative Intent Treatment for Colorectal Liver Metastases: The medical Oncologist’s perspective. 2012 Educational Book.
7.
Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052–61.PubMedCrossRef
8.
Brazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. JCO. 2008;26(33):5344–51.CrossRef
9.
Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90 day mortality after surgery for hepatic colorectal metastases. JCO. 2006;24(13):2065–72.CrossRef
10.
Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–6.PubMedCrossRef
11.
Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24.PubMedCrossRef
12.
Masi G, Loupakis F, Pollina L, et al. Long term outcome of initially unresectable metastatic colorectal cancer patients treated with FOLFOXIRI followed by radical surgery of metastases. Ann Surg. 2009;249:420–5.PubMedCrossRef
13.
Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complications rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. JCO. 2008;26:5254–60.CrossRef
14.
Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007;11:1112–9.PubMedCrossRef
15.
Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? JCO. 2006;24:3939–45.CrossRef
16.
Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.PubMedCrossRef
17.
De Jung MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;2009:440–8.
18.
Nathan H, De Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010;210:755–66.PubMedCrossRef
19.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;240:309–18.CrossRef
20.
• André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51. Phase III trial that showed FOLFOX adjuvant therapy improves survival in stage III disease. Data may be extrapolated to liver-limited liver resection in stage IV disease.PubMedCrossRef
21.
Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. J Clin Oncol. 2007;25:3456–61.PubMedCrossRef
22.
Ychou M, Raoul J-L, Douillard J-Y, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20:674–80.PubMedCrossRef
23.
Van Cutsem E, Labianca R, Bodoky G, et al. Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. J Clin Oncol. 2009;27:3117–25.PubMedCrossRef
24.
Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. J Clin Oncol. 2011;29:11–6.PubMedCrossRef
25.
De Gramont A, Van Cutsem E, Tabernero J, et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. ASCO Meeting Abstracts. 2011;29:362.
26.
Alberts SR, Sargent DJ, Smyrk CJ, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol. 2010; 28:(suppl; abstr CRA3507).
27.
Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20(12):1964–70.PubMedCrossRef
28.
Kemeny NE, Jarnagin WR, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. JCO. 2011;29:884–9.CrossRef
29.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.PubMedCrossRef
30.
Van Cutsem E M.D., Ph.D., Köhne C-H M.D., Hitre E M.D., Ph.D., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.PubMedCrossRef
31.
Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.PubMedCrossRef
32.
Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin(Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62.PubMedCrossRef
33.
Maughan TS, Adams RA, Smith CG, et al. MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14.PubMedCrossRef
34.
Ranpura V MD, Hapani S MD, Wu S MD, PhD. Treatment-related mortality with bevacizumab in cancer patients, a meta-analysis. JAMA. 2011;305(5):487–94.PubMedCrossRef
35.
Pessaux P, Marzano E, Casnedi S, et al. Histological and immediate postoperative outcome after preoperative cetuximab: case matched control study. World J Surg. 2010;34:2765–72.PubMedCrossRef
36.
37.
Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. JCO. 2007; 4134.
38.
Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomized phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94(6):798–805.PubMedCrossRef
39.
Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.PubMedCrossRef
40.
Vamvakas L, Athanasiadis A, Karampeazis A, Kakolyris S, et al. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). Crit Rev Oncol Hematol. 2010;76(1):10.CrossRef
Metadaten
Titel
Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer
verfasst von
Anya Litvak
Leonard Saltz
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 2/2013
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0160-y

Weitere Artikel der Ausgabe 2/2013

Current Colorectal Cancer Reports 2/2013 Zur Ausgabe

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Irreversible Electroporation: a Novel Option for Treatment of Hepatic Metastases

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Colorectal Cancer in the Elderly: How Do We Tailor Treatment with Chemotherapy and Radiotherapy Most Appropriately?

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Quality of Life and Functions After Chemoradiation for Rectal Cancer: A Review of Recent Publications

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

How Could the TNM System Be Best Adapted for Staging Rectal Cancer in the Future?

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Safety of Simultaneous Bowel and Liver Resections for Colon and Rectal Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise